Biotechnology Market Research Reports & Industry Analysis

... Europe Biosimilars Market & Pipeline Insight” Report Highlight: Biosimilars Market Overview & Trend Analysis by Country Biosimilars Introduction Timeline in Europe Biosimilars Development & Market Authorization Guidelines Biosimilars Clinical Pipeline by Phase, Indication, Company & Country Marketed ...

... biosimilars products being developed owing to a significant number of leading brands of biologic drugs losing their patents by 2020. “Global Biosimilars Market Regulations & Pipeline Insight” Report Highlights: Market Overview Detailed Regulatory Pathways For 12 Countries/Regions Global Biosimilars Pipeline by Phase, Indication, Company & Country Biosimilars Pipeline ...

... , the FDA published new guidance on the requirements for developing biosimilars for the US market – specifically focused on clinical pharmacology requirements ... , but potentially how they are used by physicians. In light of the FDA's new guidance, FirstWord is polling US-based oncologists and rheumatologists ...

... , to legal challenges and questions about its profitability, The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events provides ... and most up-to-date access to recent and future events in the biosimilars market, including battles being waged over policy, regulatory, intellectual ...

... of the bio-based chemical fiber industry and its raw materials in China. 2. In recent years, conventional plasticizers have received ... biomass PVA industry and will further devote itself to its development. 8. A new production process developed will effectively lower the production costs of succinic acid ...

... are physicians ready for biosimilars and is the industry doing enough to educate who is arguably the key stakeholder in this market? As physician ... for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say majority of physicians, but caveats remain In a ...

... is not, significant. That is where the Biosimilar Index comes in. A new force in biosimilar and NCB drug and market tracking FirstView’s Biosimilar Index is a new, comprehensive drug intelligence ... both on-going tracking of development and interpretation of the commercial and clinical significance. Two class beating services in one subscription! Biosimilar Index: Pipeline Database ...

... and allow online work with the project data to print or export an individual report. With the approval and launch of next generation Her2 ... cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

... what do physicians think? What do they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask US and EU5-based oncologists and rheumatologists: What naming convention for biosimilar products they believe ...

... in India. Till date around six major private players, both Indian as well subsidiaries of international companies are operating in the stem cell banking market of India. “India Cord Blood Stem Cell Banking Market” research report outlines following aspects related to booming stem cell banking in India: India Stem Cell Research & Therapy Market Overview Cord Blood Stem Cell Banking ...

... governments and private players worldwide stepping into this industry, the market shows bright prospects and immense opportunities to cash in on. As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global EPO biosimilars market will grow at a CAGR of around 37% ...

... to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on what its availability will ... drug) or across the HER2-positive breast cancer treatment paradigm? How confident they are in using CANMAb given the relative size ...

Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market ... transplant Transplant Medicine Regenerative Medicine Others Cord Blood Banking Blood Transfusion Cell Based Genetics Global Stem cell UCB market by Geography UCB market ...

... of the global market for biosimilars by 2020. “South Korea Biosimilar Market Analysis” reports gives comprehensive details on following aspects related to Biosimilar development in South Korea: Market Overview Favorable Market Parameters Biosimilar Pipeline Analysis by Company, Phase ...

... world in biosimilar sales. Although the European experience differs markedly from the anticipated evolution of biosimilars in the US, there are lessons to be learned. In Commercialisation of Biosimilars: strategies for ... of how to design strategies to influence key opinion leaders Understand why biosimilar acceptance is slower than most new generic drugs Commercialisation of Biosimilars: strategies for market penetration ...

The collection includes the following reports: Charting the Biosimilar and Biobetter Development Pipeline (2013) Biosimilar Defensive Plays - assessing the options Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets (Volume 1 and Volume 2)

... emerging market experience in India and Mexico. Rituximab biosililar pipeline, and the current status of clinical development What are the Innovator's strategy in protecting rituximab franchise? Competition to biosimilar rituximab ...

... of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

... Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, ... parameters for each drug profile in development phase are covered in “Global Cell Therapy Pipeline Analysis” research report: Drug Profile Overview ...

... the development of biological drugs in the next few years. In recent years, China bio-pharmaceuticals industry develops rapidly, but antibody drugs lag ... products in the future. Monoclonal antibody still belongs to high-end products in China market, which mainly depends on import. In 2012, the market scale ...

... , losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the ... ) comes in. Scope Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to: Understand the landscape of biosimilar/biobetter development ...

... . This insightful report brings you completely up to date with the biosimilar competitive landscape, and gives you the information you need ... .” Warwick Smith, director-general, British Generic Manufacturers Association Biosimilar Defensive Plays - assessing the options is designed to answer your strategic and ...

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated ...

... in the stem cell banking market of India. “India Stem Cell Banking Market Analysis” research report outlines following aspects related to booming stem cell banking in India: India Stem Cell Research & Therapy Market Overview Stem Cell Banking Market Overview Cord Blood & Menstrual Banking Cost Analysis ...

The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituximab), Merck ...

... forces as compared to generics, a number of companies aim to exploit this – Japan has seen a flood like consolidation and partnering activities in biosimilar ... , Yoshindo etc. to be amongst the key players in biogenerics business in Japan. In this piece, we attempt to evaluate the future competitive landscape of ...

... rates of stem cell banking ranging from 15% to 30%. Regions such as, US, Europe, China and India have low penetration ... stem cells from embryos. The report titled ‘Indian Stem Cell Banking Market: Trend and Opportunities (2012-2017)’ provides an in-depth analysis of the Indian stem cell banking market ...

... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

... one third for the global biosimulation market. Europe is the fastest growing market for biosimulation the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and development. Asian market ...

... barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential ... their impact on Market Opportunity Global Regulatory Process and Hurdles Risk/Reward profile of developing Herceptin biosimilar

... 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. “India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India like Market Overview, Biosimilar Pipeline Analysis, Biosimilar Development Capabilities ...

The report is sent in 0-2 business days after order is placed. The stem cell research in India is in its nascent stage and is gradually on a growth path of acceptance by ... covers the market size and growth prospect of the stem cell banking market in India. In addition to these, the report gives a snapshot of ...

... lower return on investments continues to challenge the attractiveness of the biosimilars market. The report analyzes the global biosimilars market. The various drivers and challenges faced by the ...

The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivi...

For the past few years, the biosimilars industry has been growing stupendously across the globe due to increasing healthcare costs and rising aging population. It is expected to evolve, to a great ext...

Across the globe, the biosimilars industry has been growing stupendously for the past few years. Increasing healthcare costs and rising aging population are driving the industry that is expected to ev...

Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...

Antibody medicine is generally obtained from monoclonal antibody through genetic engineering, possessing the advantages of strong targeting and few drug side effects. At the present time, it is mainly...

The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid po...

It was supposed to be the “epoch of biosimilars”, or drugs that copied existing biologics but had the potential to be more cost-effective. Yet five years later, biosimilars have failed to reach their...

... and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and ... , Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary ...

Single User PDF Format: US$ 1,400.00 Multi-User License: US$ 1,800.00 Hard Copy: US$ 1,500.00 CD-ROM: US$ 1,500.00 The global biosimilars industry has been growing stupendously since t...

China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market...

... Brazil biomaterial market. Plus, the report offers a detailed analysis of the market trends, opportunities, and the factors influencing the growth of each segment of the biomaterials market ...

... biomaterials is expected to reach $64.7 billion in 2015 from $25.6 billion in 2008 with a CAGR of 15% from 2010 to 2015. In 2010, the orthopedic biomaterial market recorded revenues of $12 billion or 37.5% of the total global biomaterial market ... , at a CAGR of 12.7% (2010 to 2015) because the market is relatively mature compared to other product markets. Cardiovascular biomaterial is the second-highest market, and contributed 36.1% to the global biomaterial market in 2010. With the ...

Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,400.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 900.00 The stem cell market has been growing at a fast pace for the past few yea...

From Canada and the US to Japan, the EU and Australia, regulators around the world are establishing guidelines that will pave the way for competition between biosimilars and costly biologics. For many...

They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written. Yet for the pharmaceutical industry, biosimilar monoclonal antibodies...

This report analyzes the US Market for Stem Cells Research in US$ Million. Annual forecasts are provided for the period 2006 through 2015. The ... , Inc., Osiris Therapeutics, StemCells, Inc., ThermoGenesis Corp., and ViaCord, LLC. Market data and analytics are derived from primary and secondary research. ...

... previously been no effective treatment. The medical stem cells market is divided into three categories: stem cell therapeutics, cord blood banking and drug ... projected to be the second largest and second fastest growing market. US is the major stem cell market in the world and has recently been boosted by ...